Impaired neurogenesis and neural progenitor fate choice in a human stem cell model of SETBP1 disorder.
Lucia F Cardo, Daniel C de la Fuente, Meng Li
PMID 36805818WHAT IT FOUND
In a stem cell model of SETBP1 disorder, loss of the gene caused neural progenitors to keep dividing instead of becoming neurons.
This was driven by overactive Wnt signaling. Blocking Wnt with a drug restored normal neuron production and ventral brain cell fate.
Key findings
01SETBP1 deficiency causes neural progenitors to remain in a proliferative state longer than controls, reducing the number of neurons produced.
02The proliferative defect is linked to elevated Wnt/beta-catenin signaling, which is not observed in heterozygous cells to the same extent.
03Pharmacological inhibition of Wnt signaling with XAV939 rescues the neuronal production defect and improves ventral forebrain fate induction in SETBP1-deficient cells.
STILL TO COME
How it was doneWhat they foundWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study used stem cell models, not patients, so it cannot confirm if these mechanisms operate identically in human brains. The most severe defects were seen in homozygous (two-copy loss) cells, but SETBP1 disorder is caused by heterozygous (one-copy loss) mutations. Heterozygous cells showed milder or no deficits in proliferation, suggesting other factors may be needed to fully replicate the human phenotype. The study did not assess functional outcomes like connectivity or behavior.
Declared interests
None declared. The work was supported by non-U.S. government funding.
The easy way to misread this
Do not interpret the rescue by Wnt inhibition as a current treatment option for patients. This was an in vitro experiment on stem cells, and the drug XAV939 is not approved for human use in this context.